Moderna announces phase 2 data on mrna-4157/v940, an investigational mrna personalized cancer vaccine, to be presented at the 2023 aacr annual meeting

Cambridge, ma / accesswire / march 14, 2023 / moderna, inc. (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, today announced that two abstracts on mrna-4157/v940 an investigational mrna personalized cancer vaccine, have been accepted for presentation at the 2023 american association of cancer research (aacr) annual meeting being held april 14-19 in orlando, fl. mrna-4157/v940 is being jointly developed by moderna and merck, known as msd outside of the united states and canada.
MRNA Ratings Summary
MRNA Quant Ranking